ASHP voiced its support this week for legislation that reauthorizes FDA prescription drug user fees. I
ASHP voiced its support this week for legislation that reauthorizes FDA prescription drug user fees. In an Aug. 28 letter to Sen. Edward Kennedy (D, Mass.), ASHP executive VP/CEO Henri R. Manasse Jr. wrote, "ASHP believes that maintaining the safety of our drug supply is a critical component of effective patient care." Manasse said the association supports several provisions in the legislation, including enabling the FDA to require the scrutiny of drugs under the Risk Evaluation and Mitigation Strategy (REMS), establishing a clinical trial registry and clinical trial results database for phase II-IV clinical trials, and increasing the oversight of direct-to-consumer advertising of specific prescription drugs.
Click here to see more articles from Drug Topics Daily News.
To go to the Drug Topics homepage, click here.